Cereno Scientific terminates agreement with Redeye regarding equity research coverage
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that the company has terminated the agreement with Redeye regarding equity research coverage.For further information, please contact: Jonas Fogelberg, Interim CFOEmail: info@cerenoscientific.comhttp://www.cerenoscientific.com/ About Cereno Scientific AB Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the